Available Trials

• Breast
• Hematology
• Leukemia
• Lung - Non-Small Cell Lung
• Lymphoma
• Multiple Myeloma
• Pancreas
• PNH
• Solid Tumor

Breast

• NEW: USOR 18042 A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study Of Talazoparib For Neoadjuvant Treatment Of Germline BRCA 1/2 Mutation Patients With Early Triple-Negative Breast Cancer. (C3441020)

  Available at: Niles

  ---

• ECOG-ACRIN S1207 A Phase III, Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer.

  Available at: Niles

  ---

• ECOG-ACRIN 1131 A Randomized, Phase III Post-Operative Trial of Platinum Base Chemotherapy vs Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Therapy.

  Available at: Niles

  ---

• USOR 16128 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study. (A5481081)

  Available at: Niles

  ---

Hematology

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles

  ---

Leukemia

• AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.

  Available at: Niles

  ---

• ECOG-ACRIN 1910 A Phase III, Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults.

  Available at: Niles

  ---

Lung - Non-Small Cell Lung

• USOR 17063/TSR-022: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors: NSCLC. USOR 17063 (4020-01-001)

  Available at: Niles

  ---

• ECOG-ACRIN S1400 2nd Line A Phase II/III, Biomarker-Driven Master Protocol For Previously Treated Squamous Cell Lung Cancer. - A Phase II Study of Talazoparib in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer. - A Phase III Randomized Study of Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Lung Cancer and No Matching Biomarker.

  Available at: Niles

  ---

• ECOG-ACRIN-4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

  Available at: Niles

  ---

• USOR 16156 A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer. (CA209-817)

  Available at: Niles

  ---

• USOR 16161 A Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum-Doublet Chemotherapy in Early Stage NSCLC. (CA209-816)

  Available at: Niles

  ---

Lymphoma

• USOR 17050 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL.) USOR 17050/GO39942. Contact Project Manager Status.

  Available at: Niles

  ---

• USOR 17093/CITADEL-205 A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Ka Inhibitor, In Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) - INCB050465-205.

  Available at: Niles

  ---

• USOR 17041 Screening Protocol for STAR USOR 16248: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects with Diffuse Large B Cell Lymphoma. USOR 17041

  Available at: Niles

  ---

• USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

  Available at: Niles

  ---

• USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)

  Available at: Niles

  ---

Multiple Myeloma

• USOR 17081 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen. USOR 17081 (C16038) Ph4 Ixazomib+Lena & Dex MM (MM-6)

  Available at: Niles

  ---

• USOR 16035 Registry - A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - The Insight MM Study. (NSMM-5001)

  Available at: Niles

  ---

Pancreas

• NEWLY OPENED USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

  Available at: Niles

  ---

• USOR 16187: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (AM0010-301) USOR 16187

  Available at: Niles

  ---

PNH

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles

  ---

Solid Tumor

• USOR 16041 AN OPEN-LABEL PHASE 2 MULTI-COHORT TRIAL OF NIVOLUMAB IN ADVANCED OR METASTATIC MALIGNANCIES. HOLDING. CONTACT RESEARCH FOR OPEN COHORTS. USOR 16041 (CA 209-627)

  Available at: Niles

  ---